Added to YB: 2024-09-24
Pitch date: 2024-06-30
INSM [bullish]
Insmed Incorporated
+196.48%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Market Cap
$41.2B
Pitch Price
$66.45
Price Target
N/A
Dividend
N/A
EV/EBITDA
-42.82
P/E
-31.07
EV/Sales
90.08
Sector
Biotechnology
Category
growth
Show full summary:
Janus Henderson Global Life Sciences Diversified ADR Managed Account Portfolio Holding: Insmed Incorporated
INSM: Positive phase 3 results for brensocatib in bronchiectasis, affecting 1M+ globally. No approved treatments exist. Potential blockbuster drug ($1B+ annual sales) for lung disease causing widened airways, infections, chronic cough. Top contributor to portfolio.
Read full article (1 min)